

CLAIMS

sub
C2

1. A method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway, the method comprising administering, to the subject, an effective amount of a catalyst which is said enzyme or an enzymatically equivalent part or analogue thereof.

2. A method according to claim 1, wherein the disease is selected from the group consisting of

- 10 acute intermittent porphyria (AIP),
ALA deficiency porphyria (ADP),
Porphyria cutanea tarda (PCT),
Hereditary coproporphyria (HCP),
Harderoporphyria (HDP),
15 Variegata porphyria (VP),
Congenital erythropoietic porphyria (CEP),
Erythropoietic protoporphyria (EPP), and
Hepatoerythropoietic porphyria (HEP).

pub
C3

20 3. A method according to claim 1 or 2, wherein the catalyst is an enzyme selected from the group consisting of

porphobilinogen deaminase (PBGD)
ALA dehydratase,
Uroporphyrinogen decarboxylase,

- 25 Coproporphyrinogen oxidase,
Coproporphyrinogen oxidase,
Protoporphyrinogen oxidase,
Uroporphyrinogen III synthase,
Ferrochelatase, and

30 Uroporphyrinogen decarboxylase,
or an enzymatically equivalent part or analogue thereof.

claim 1

a 4. A method according to any of the preceding claims, wherein the disease is AIP and the enzyme is PBGD or an enzymatically equivalent part or analogue thereof.

SUG a
c3
Cont'd
5. A method according to ^{*claim 1*} ~~any of the preceding claims~~, wherein the catalyst is a recombinant form of the enzyme belonging to the heme biosynthetic pathway or of the enzymatically equivalent part or analogue thereof.

5
6. A method according to ^{*claim 1*} ~~any of the preceding claims~~, wherein the catalyst is administered by a route selected from the group consisting of the intravenous route, the intraarterial route, the intracutaneous route, the subcutaneous route, the oral route, the buccal route, the intramuscular route, the anal route, the transdermic route, the intradermal route, and the intratechal route.

10
a
7. A method according to ^{*claim*} ~~any of claims 1-6~~, wherein the catalyst is formulated in an isotonic solution, ~~such as 0.9% NaCl and 10-50 mM Sodium-phosphate pH 6.50 to 8 or Sodium-phosphate, glycine, mannitol or the corresponding potassium salts.~~

a
15 8. A method according to ^{*claim*} ~~any of claims 1-7~~, wherein the catalyst is lyophilised.

a
9. A method according to ^{*claim*} ~~any of claims 1-8~~, wherein the catalyst is sterile filtered.

a
20 10. A method according to ^{*claim*} ~~any of claims 1-6, 8 or 9~~, wherein the catalyst is formulated as lipid vesicles comprising phosphatidylcholine or phosphatidylethanolamine or combinations thereof.

a
11. A method according to ^{*claim*} ~~any of claims 1-6, 8 or 9~~, wherein the catalyst is incorporated into erythrocyte ghosts.

25
a
12. A method according to ^{*claim*} ~~any of claims 1-6, 8 or 9~~, wherein the catalyst is formulated as a sustained release formulation involving ^{*comprising*} ~~biodegradable microspheres, such as microspheres comprising polylactic acid, polyglycolic acid or mixtures of these.~~

a
30 13. A method according to ^{*claim*} ~~any of claims 1-9~~, wherein the catalyst is lyophilized in a two-compartment cartridge, where the catalyst will be in the front compartment and water for reconstitution in the rear compartment.

14. A method according to claim 13, wherein the two compartment cartridge is combined with an injection device to administer the catalyst either by a needle or by a needle-less (high pressure) device.

claim
α 5 15. A method according to ~~any of claims 1-9~~, wherein the catalyst is formulated in a physiological buffer containing an enhancer for nasal administration.

claim 1
α 16. A method according to ~~any of the preceding claims~~, wherein the catalyst is formulated as an oral formulation containing lipid vesicles, ~~such as those comprising~~
α 10 ~~phosphatidylcholine, phosphatidylethanolamine, or sphingomyelin, or dextrane-~~
α ~~microspheres.~~

claim 1
α 17. A method according to ~~any of the preceding claims~~, wherein the catalyst is formulated so as to enhance the half-life thereof in the subject's bloodstream.

15

18. A method according to claim 17, wherein the catalyst has a polyethylene glycol coating.

19. A method according to claim 17, wherein the catalyst is complexed with a heavy
20 metal.

claim
α 20. A method according to ~~any of the preceding claims~~, wherein the catalyst is an enzymatically equivalent part or analogue of the enzyme and exerts at least part of its enzymatic activity intracellularly upon administration to the subject.

25

21. A method according to claim 20, wherein the catalyst is a small artificial enzyme or an organic catalyst which can polymerize porphobilinogen to hydroxymethylbilane

claim
α 22. A method according to ~~any of claims 1-9~~, wherein the catalyst is said enzyme
30 formulated in such a manner that it exerts at least part of its enzymatic activity intracellularly upon administration to the subject.

23. A method according to claim 22, wherein the catalyst is tagged with specific carbohydrates or other liver cell specific structures for specific liver uptake.

a 24. A method according to claim ~~1-19~~, wherein the catalyst exerts substantially all its enzymatic activity extracellularly in the bloodstream.

25. A method according to claim 24, wherein the enzymatic activity of the catalyst on
5 its relevant heme precursor results in a metabolic product which 1) either moves into
~~the intracellular compartment and is converted further via the remaining steps of the~~
heme biosynthetic pathway or 2) is excreted from the subject via urine and/or faeces.

a 26. A method according to ^{claim 1} ~~any of the preceding claims~~, wherein the catalyst has been
10 prepared by a method comprising

- 20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
- a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid sequence encoding the catalyst;
 - b) transforming a compatible host cell with the vector;
 - 15 c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence; and
 - d) recovering the expression product from the culture
- and optionally subjecting the expression product to post-translational processing, such as in vitro protein refolding, enzymatic removal of fusion partners, alkylation of amino acid residues, and deglycosylation, so as to obtain the catalyst.

a 27. A method according to ^{claim 1} ~~any of claims 1-25~~, wherein the catalyst has been prepared by liquid-phase or solid-phase peptide synthesis.

a 25 28. A method according to ^{claim 1} ~~any of the preceding claims~~, wherein the catalyst is free from any other biological material of human origin.

a 29. A method according to ^{claim 1} ~~any of the preceding claims~~, wherein the catalyst is administered at least once a day, ~~such as 2, 3, 4, and 5 times daily.~~

30
a 30. A method according to ^{claim 1} ~~any of the preceding claims~~ wherein the daily dosage is in the range of 0.01 – 1.0 mg/kg body weight per day, ~~such as in the range of 0.05 – 0.5 mg/kg body weight per day.~~

Claim 1
 31. A method according to ~~any of the preceding claims~~, wherein the daily dosage is about 0.1 mg-per kg-body-weight per day.

A pharmaceutical composition comprising
 32. A catalyst which is an enzyme of the heme biosynthetic pathway or an enzymatically equivalent part or analogue thereof, ~~for use as a medicament.~~

33. Use of a catalyst which is an enzyme of the heme biosynthetic pathway or an enzymatically equivalent part or analogue thereof for the preparation of a pharmaceutical composition for the treatment or prophylaxis of diseases caused by deficiency of said enzyme.

34. The use according to claim 33, wherein the treatment or prophylaxis is performed according to any of claims 1-31.

Claim
 35. A method according to ~~any of claims 1-31~~ wherein the catalyst is a recombinant form of the enzyme.

Claim
 36. A method according to ~~any of claims 1-31~~ wherein the catalyst is recombinant human PBGD based on any of Seq. ID NO 1 (clone PBGD 1.1) and Seq. ID NO 12 (non-erythro PBGD 1.1.1).

37
 37. A catalyst according to claim 32, which is recombinant human PBGD based on any of Seq. ID NO 1 (clone PBGD 1.1) and Seq. ID NO 12 (non-erythro PBGD 1.1.1).

38
 37. A method for treating a patient having a mutation in the PBGD gene causing an enzyme defect, comprising the use of a human PBGD cDNA sequence of either non-erythropoietic form or erythropoietic form according to the tissue in which PBGD should be expressed, and transfection of the patient with the relevant cDNA.

39
 38. The method according to claim 37 wherein the enzyme deficiency is selected from enzyme deficiencies resulting in a disease selected from Acute Intermittent Porphyria, (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital

erythropoietic porphyria (CEP), Erythropoietic protoporphyria (EPP), and
Hepatoerythropoietic porphyria (HEP).

40 The method according to claim 39 wherein the disease is Acute Intermittent

5 Porphyria, (AIP).

41 The method according to ~~any of claims 37-39~~ ^{claim} wherein the human PBGD cDNA sequence is selected from Seq. ID NO 1 (clone PBGD 1.1) and Seq. ID NO 12 (non-erythro PBGD 1.1.1)

42 The method according to ~~any of claims 37-40~~ ^{claim} wherein the transfection is by use of a vector selected from ~~adenovirus, retrovirus and associated adenovirus.~~ ^{the group consisting of}

43 The method according to ~~any of claims 37-41~~ ^{claim} wherein the PBGD gene transfer vector into human cells (erythropoietic and/or non-erythropoietic) results in normal PBGD activity.

44 A method of gene therapy treatment of patients with Acute Intermittent Porphyria (AIP) ^{comprising} by a correction of one of the specific point mutations identified causing AIP by use of chimeraplasty gene repair.

45 The method according to any of claims 43 wherein the delivery system for transfection is by use of non-viral vectors formulated in a vehicle preparation comprising one or more components selected from cationic phospholipids, phospholipids, phospholipids mixed with neutral lipids, lictosylated PEI, liposomes liposomes comprising mixtures of natural phospholipids and neutral lipids.

46 A method according to claim 43 ~~or 44~~ wherein the mutation is selected from Table A.

add
C7